Drug intelligence / Profile preview

LE-AD-201

Development stage: Preclinical
Lead developer: Akrocell Biosciences
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

LE-AD-201 is a species-specific, feline mesenchymal stem cell (MSC)-derived exosome therapeutic being developed by Akrocell Biosciences. It is designed to address underlying immune dysregulation and inflammation in companion animals. The therapeutic is currently in preclinical development for two feline indications: feline gingivostomatitis (FCGS), a severe, immune-mediated oral inflammatory condition, and feline chronic kidney disease (FCKD), a leading cause of mortality in cats where the therapy targets immune-mediated fibrotic progression through systemic immunomodulation.

Beyond the preview

Go deeper on LE-AD-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LE-AD-201.

Explore the full profile